Biotech startup Voronoi scraps IPO plan Startup has failed to draw enough bids for planned listing
Translated by Kim So-in 공개 2022-03-17 08:12:05
이 기사는 2022년 03월 17일 07:57 thebell 에 표출된 기사입니다.
South Korea’s biotech startup Voronoi has scrapped its plan to go public after getting lukewarm response from institutional investors in its two-day bookbuilding process.Voronoi has cancelled its initial public offering (IPO) plan as it only drew bids from some 20 institutions in its bookbuilding, according to industry sources on Tuesday. Most of the institutions decided not to make bids at the last minute.
“The company’s growth potential was high, but many of the institutions decided not to participate in the bookbuilding amid unfavorable market conditions,” an official at one asset management firm in Seoul said. “All of the asset managers I know made their final decisions to withdraw this time.”
Voronoi had to attract bids worth 100 billion won ($80 million) based on the bottom end of its price range, but the bids drawn were worth much less than that.
Voronoi was valued at 1.2 trillion won in its 100 billion won pre-IPO funding round in 2019, but had to lower its valuation following two failures in technology evaluations.
The biotech startup could have been the first unicorn going public in the country to benefit from a special exemption for listing. This allows companies to apply for preliminary review for listing on the Kosdaq if their market capitalization exceeds 500 billion won and pass technology evaluation from one independent evaluating agency instead of two. Voronoi received an A rating from Korea Technology Finance Corporation and valued itself at as high as 860 billion won in its registration statement.
Voronoi CEO Kim Dae-kwon himself conducted IR session for the firm’s successful market debut, but failed to attract positive response amid frozen investor sentiment toward biotech firms. (Reporting by Chan-mi Oh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [Company Watch]'수익성 개선' 삼보모터스, 체코법인 선전 영향
- [Red & Blue]'양자보안' 엑스게이트, 구글·IBM 발표에 주가 탄력
- [Board Match up/모두투어 vs 노랑풍선]배당 재개 모두투어, 4년째 멈춘 노랑풍선
- [ROE 분석]수요 증가의 힘, 날개 단 SK하이닉스
- [Financial Index/대한항공]지주사 행위 제한 요건 풀어야 할 고리는
- 노랑풍선, 재무 건전성 기반 '풋옵션' 침착 대응
- [루키 바이오텍 in market]국산 면역항암제 도전 이뮨온시아, 당위성도 가능성도 있다
- 재무·글로벌 힘 싣는 삼일제약, 권태근 CFO 부사장 승진
- [thebell interview/하이테크 소부장 리포트]하나마이크론 "글로벌 반도체 후공정 5위권 진입 목표"
- [큐로셀 첫 '국산 CAR-T' 도전]R&D 헤드가 말한 안발셀 핵심은 OVIS "다음은 고형암"